Our results suggest that the use of agents targeting BCL‐2, either alone or in combination with other conventional drugs, represents a novel and promising approach for EBV‐positive B lymphoproliferative disorders, such as PTLD. This evidence concerns the gene BCL2 and post-transplant lymphoproliferative disease.